Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 27, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Beyond the Primary Tumour: Rethinking Biomarker Strategies in Recurrent Renal Cell Carcinoma

Zayd Tippu1, Lewis Au2, Samra Turajlić3

  • 1Cancer Dynamics Laboratory, Cancer Research UK Manchester Institute, Manchester, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK; Skin & Renal Unit, The Royal Marsden NHS Foundation Trust, London, UK.

European Urology
|June 25, 2026
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Experiment Videos

Last Updated: Jun 27, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

Nature communications·2026
Same author

Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141].

European urology open science·2026
Same author

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Nature communications·2026
Same author

Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.

Nature machine intelligence·2026
Same author

Advanced imaging of immune cells for human kidney disease.

Trends in molecular medicine·2026
Same author

Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.

Nature communications·2026